References
- 1. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J Environ Res Public Health. 2018;15(11):2589.
- 2. Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril. 2016;106(1):16-24.
- 3. Khan MJ, Ullah A, Basit S. Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. Appl Clin Genet. 2019;12:249-260.
- 4. Ekpenyong CE, Davis KJ, Akpan UP, Daniel NE. Academic stress and menstrual disorders among female undergraduates in Uyo, South Eastern Nigeria – the need for health education. Niger J Physiol Sci. 2011;26(2):193-198.
- 5. Rafique N, Al-Sheikh MH. Prevalence of menstrual problems and their association with psychological stress in young female students studying health sciences. Saudi Med J. 2018;39(1):67-73.
- 6. Dokras A, Stener-Victorin E, Yildiz BO et al. Androgen Excess – Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril. 2018;109(5):888-899.
- 7. Livadas S, Chaskou S, Kandaraki AA et al. Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2011;75(5):698-703.
- 8. Ilie IR. Neurotransmitter, neuropeptide and gut peptide profile in PCOS-pathways contributing to the pathophysiology, food intake and psychiatric manifestations of PCOS. Adv Clin Chem. 2020;96:85-135.
- 9. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53(4):865-871.
- 10. Kyrou I, Tsigos C. Chronic stress, visceral obesity and gonadal dysfunction. Hormones (Athens). 2008;7(4):287-293.
- 11. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042.
- 12. Benson S, Arck PC, Tan S et al. Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology. 2009;34(5):727-35.
- 13. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618.
- 14. Dewailly D, Alebić MŠ, Duhamel A, Stojanović N. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles. Hum Reprod. 2014 Nov;29(11):2536-43.
- 15. Robeva R, Nedyalkova M, Kirilov G, et al. Multivariate Statistical Approach for Nephrines in Women with Obesity. Molecules. 2021;26(5):1393.
- 16. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol (Oxf). 2012;77(6):791-801.
- 17. Lansdown AJ, Warnert EAH, Sverrisdóttir Y, Wise RG, Rees DA. Regional Cerebral Activation Accompanies Sympathoex-citation in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019;104(9):3614-3623.
- 18. Garcia-Rudaz C, Armando I, Levin G et al. Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1998;49(2):221-228.
- 19. Mehde А, Mehdi W, Aboud W, Hmeed R. Utility of plasma free metanephrines for detecting insulin resistance in patients with PCOS. BCAIJ. 2014, 8(1), 44-49.
- 20. Sam S, Vellanki P, Yalamanchi SK et al. Exaggerated glucagon responses to hypoglycemia in women with polycystic ovary syndrome. Metabolism. 2017;71:125-131.
- 21. Chaudhari NK, Nampoothiri LP. Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model. Horm Mol Biol Clin Investig. 2017;29(2):71-77.
- 22. Saller S, Merz-Lange J, Raffael S et al. Norepinephrine, active norepinephrine transporter, and norepinephrine-metabolism are involved in the generation of reactive oxygen species in human ovarian granulosa cells. Endocrinology. 2012;153(3):1472-1483.
- 23. Reimann M, Qin N, Gruber M et al. Adrenal medullary dysfunction as a feature of obesity. Int J Obes (Lond). 2017;41(5):714-721.
- 24. Zumoff B, Strain GW. A perspective on the hormonal abnormalities of obesity: are they cause or effect? Obes Res. 1994;2(1):56-67.
- 25. Lopez MG, Abad F, Sancho C et al. Membrane-mediated effects of the steroid 17-α-estradiol on adrenal catecholamine release. J Pharmacol Exp Ther 1991;259(1):279-285.
- 26. Park YH, Cho GS, Cho ET et al. Influence of 17-alpha-estradiol on catecholamine secretion from the perfused rat adrenal gland. Korean J Intern Med. 1996;11(1):25-39.
- 27. De Miguel R, Fernández-Ruiz JJ, Hernández ML, Ramos JA. Role of ovarian steroids on the catecholamine synthesis and release in female rat adrenal: in vivo and in vitro studies. Life Sci. 1989;44(25):1979-86.
- 28. Del Rio G, Velardo A, Menozzi R et al. Acute estradiol and progesterone administration reduced cardiovascular and catecholamine responses to mental stress in menopausal women. Neuroendocrinology. 1998;67(4):269-274.
- 29. Weise M, Eisenhofer G, Merke DP. Pubertal and gender-related changes in the sympathoadrenal system in healthy children. J Clin Endocrinol Metab. 2002;87(11):5038-5043.
- 30. Heider U, Pedal I, Spanel-Borowski K. Increase in nerve fibers and loss of mast cells in polycystic and postmenopausal ovaries. Fertil Steril. 2001;75(6):1141-1147.
- 31. Dyer CA, Erickson GF. Norepinephrine amplifies human chorionic gonadotropin-stimulated androgen biosyn-thesis by ovarian theca-interstitial cells. Endocrinology. 1985;116(4):1645-1652.
- 32. Morales-Ledesma L, Linares R, Rosas G, et al. Unilateral sectioning of the superior ovarian nerve of rats with polycystic ovarian syndrome restores ovulation in the innervated ovary. Reprod Biol Endocrinol. 2010;8:99.
- 33. Shorakae S, Lambert EA, Jona E et al. Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome-A Randomized Controlled Trial. Front Physiol. 2018;9:1486.
- 34. Haidan A, Bornstein SR, Glasow A et al. Basal steroidogenic activity of adrenocortical cells is increased 10-fold by coculture with chromaffin cells. Endocrinology. 1998;139(2):772-780.
- 35. Ehrhart-Bornstein M, Bornstein SR, Güse-Behling H et al. Sympathoadrenal regulation of adrenal androstenedione release. Neuroendocrinology. 1994;59(4):406-412.
- 36. Straub RH, Kittner JM, Heijnen C, Schedlowski M, Schmidt RE, Jacobs R. Infusion of epinephrine decreases serum levels of cortisol and 17-hydroxyprogesterone in patients with rheumatoid arthritis. J Rheumatol. 2002;29(8):1659-1664.
- 37. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev. 1998;19(2):101-43.
- 38. Ellulu MS, Patimah I, Khaza›ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863.